By Ananta Agarwal (Reuters) – U.S. railroad operators expect heatwaves across the northern hemisphere to reignite coal shipments as people crank up the air conditioning to beat the heat. Grid op[...]
Read more
July 28, 2023
Bearish traders swarm AMC options as stock conversion plan faces doubts
By Saqib Iqbal Ahmed NEW YORK (Reuters) – Shares of AMC Entertainment Holdings Inc have been hit by a wave of bearish options bets amid uncertainty over the company’s stock conversion plan[...]
Read more
Biden admin rejects GM’s warning that US emissions rules will be costly
By David Shepardson WASHINGTON (Reuters) -General Motors warned the Biden administration’s planned changes to vehicle emissions rules could cost the auto industry hundreds of billions of dollars[...]
Read more
Intel results boost chip stocks on optimism PC market slump is ending
(Corrects company name to TSMC in paragraph 6) By Aditya Soni (Reuters) – Intel shares rose over 4% on Friday, a day after the chipmaker’s unexpectedly strong quarterly report heralded a t[...]
Read more
Vietnam EV maker VinFast plans US listing in August after regulator nod
By Phuong Nguyen HANOI (Reuters) – Vietnamese electric vehicle maker VinFast is planning to list in the United States next month via a blank-cheque company after the Securities and Exchange Comm[...]
Read more
Chipmakers signal supply glut easing but demand recovery still slow
By Joyce Lee SEOUL (Reuters) – From Intel to Samsung, global chipmakers are celebrating the beginning of the end of a semiconductor supply glut, but the outlook for demand from customers outside[...]
Read more
Biogen to buy Reata for $6.5 billion to bulk up rare disease portfolio
By Manas Mishra and Bhanvi Satija (Reuters) -Biogen agreed to buy rare disease drugmaker Reata Pharmaceuticals for nearly $6.5 billion, the first large acquisition under new CEO Christopher Viehbacher[...]
Read more
Laurentian Bank’s shares fall after media report that potential top bidders bowed out
(Reuters) – Laurentian Bank of Canada’s shares fell 9% on Friday after a newspaper reported that the Montreal-based bank was struggling to find an acquirer and that Canada’s top bank[...]
Read more
AstraZeneca’s rare disease arm in $1 billion deal for Pfizer gene therapies
By Yadarisa Shabong (Reuters) -AstraZeneca said on Friday its Alexion unit had agreed to buy U.S. drugmaker Pfizer’s early-stage rare disease gene therapy portfolio for up to $1 billion, plus ro[...]
Read more